FDA warns of ‘grave’ knock-on effects from Eagle decision
The US Food and Drug Administration has warned a US Court of Appeals for the DC Circuit decision awarding market exclusivity to Eagle Pharmaceuticals for a cancer drug will have “grave” consequences for patient access.
WHO launches COVID-19 pool with 30 countries
The World Health Organization has launched a COVID-19 technology pool, with 30 countries and multiple international partners and institutions rallying together to support the initiative.
Campaigners say US govt should have remdesivir patent rights
The PrEP4All campaign has argued that the US government should own joint patent rights for remdesivir, the Gilead Sciences antiviral which is the only drug approved anywhere for treating COVID-19.
MSD buys Themis as part of COVID-19 plans
Merck Sharp & Dohme is pushing forward with three initiatives aimed at combating the COVID-19 pandemic, including the acquisition of vaccine company Themis Bioscience.
Report slams big pharma influence in EU-funded project
A new NGO report has sharply criticised the EU-funded Innovative Medicines Initiative as favouring Big Pharma over small businesses, particularly when it comes to IP.
Codexis sues rival DNA tech company over TMs
Protein engineering company Codexis has accused competitor Codex DNA of trademark infringement through the use of a “virtually identical” mark.
FDA approves Hikma’s Vascepa generic
London-based Hikma Pharmaceuticals has won approval to launch the first generic version of Vascepa, after having key Amarin patents for the heart drug invalidated.
Australia investigates counterfeit N95s in hospitals
The Australian government has ordered an investigation into the sale of counterfeit face masks in the country, following warnings from health experts and local media reports over the prevalence of fake equipment.
Personal Genomics takes PacBio dispute to Chinese court
Taiwanese biotechnology company Personal Genomics is using California’s Pacific Biosciences for patent infringement in China.
Merck KGaA wins injunction after MSD trademark suit
The English High Court has finalised the terms of a trademark injunction against US pharmaceutical company Merck, Sharp and Dohme (MSD), in favour of German rival Merck KGaA.
